ART receives regulatory approval to begin First‐In‐Man “ARTDIVA” clinical trial

PARIS, May 15, 2012—Arterial Remodeling Technologies (“ART”) reported today that it has received regulatory approval in Europe to begin its First‐In‐Man “ARTDIVA” (Arterial Remodeling Transient DIsmantling Vascular Angioplasty) clinical trial next month at five medical centers. ART’s in vivo data strongly suggest that its next‐generation bioresorbable stent is designed to promote positive arterial remodeling.


ART-News 120515